Minirin Spray (Desmopressin Acetate Trihydrate)

Desmopressin acetate, the active ingredient in Minirin Spray, is a vasopressin analog presented as a nasal spray for intranasal use. It is employed to manage central diabetes insipidus, reduce nocturnal enuresis in children and adults, and support hemostasis in certain bleeding disorders such as mild hemophilia A.

GNH USA supplies Minirin Spray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring regulatory‑aligned sourcing for diverse therapeutic needs. Our distribution network covers Europe, Asia, Africa and the Americas, with dedicated quality‑control and cold‑chain logistics where required.

Desmopressin acetate acts on the antidiuretic hormone pathway to regulate water balance and coagulation.

- Central diabetes insipidus: reduces excessive urine output by enhancing renal water reabsorption. - Nocturnal enuresis: decreases nighttime bedwetting episodes by concentrating urine and lowering urine volume. - Bleeding disorders (e.g., mild hemophilia A): raises plasma levels of factor VIII and von Willebrand factor, improving clot formation. - Von Willebrand disease: promotes release of von Willebrand factor, aiding platelet adhesion and reducing bleeding time. - Pre‑operative management of mild bleeding risk: provides temporary hemostatic support before minor surgical procedures.

Desmopressin nasal spray may cause a range of adverse reactions.

Common Side Effects: - Nasal irritation or congestion. - Headache. - Mild hyponatremia presenting as nausea or fatigue. - Thirst.

Serious or Rare Side Effects: - Severe hyponatremia leading to seizures or coma. - Water intoxication with cerebral edema. - Allergic reactions including rash, angioedema or anaphylaxis. - Nasal septum ulceration or epistaxis. - Hypertensive crisis in patients receiving concomitant vasopressin antagonists.

When prescribing or dispensing Minirin Spray, consider the following safety measures.

- Dose adjustment in renal impairment: reduce dose as renal clearance is decreased. - Monitor serum sodium: regular checks are advised, especially in elderly patients. - Avoid excessive fluid intake: limit free water to prevent water intoxication. - Use with caution in patients receiving carbamazepine or other ADH‑antagonist drugs. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Desmopressin nasal spray can interact with several medicines.

Major Interactions (Avoid): - Carbamazepine: induces metabolism and reduces desmopressin efficacy. - Other antidiuretic agents (e.g., chlorpropamide): additive risk of severe hyponatremia. - Vasopressin antagonists (e.g., conivaptan): antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may increase hyponatremia risk. - Loop diuretics (e.g., furosemide): can alter water balance and sodium levels. - SSRIs (e.g., sertraline): potential additive effect on serum sodium, requiring monitoring.